PF 08049820
Alternative Names: PF-08049820Latest Information Update: 24 Dec 2024
Price :
$50 *
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis
Most Recent Events
- 27 Nov 2024 Phase-I clinical trials in Atopic dermatitis (In volunteers) in USA (PO), (NCT06686797),
- 13 Nov 2024 Pfizer plans a phase-I trial for Atopic dermatitis (In volunteers) (PO),(NCT06686797),
- 13 Nov 2024 Preclinical trials in Atopic dermatitis in USA (PO) prior to November 2024